Genmab stock heads into the open after a 1.6% gain in Copenhagen
Published on 09/16/2026 at 06:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Genmab stock closed at DKK 2,150.00 on Nasdaq Copenhagen on September 15, 2026, marking a 1.61% gain for the session. Per exchange data, the move came as the OMX Copenhagen 20 slipped 0.84%, meaning the shares outperformed their home index on the day.
September 15, 2026 in numbers
Genmab A/S (ISIN DK0010272202, Nasdaq Copenhagen: GMAB) finished the September 15, 2026 session at DKK 2,150.00, up 34.00 index points or 1.61% on its primary Copenhagen listing, while the OMX Copenhagen 20 closed 0.84% lower, highlighting relative strength in the stock versus the broader Danish market. According to session data cited by Investing.com, Genmab was the best performer in the OMX Copenhagen 20 basket, ending the day at that DKK 2,150.00 close after adding 34.00 points.Investing.com Market commentary around the name has also noted positive six-month performance and a valuation multiple around the mid-20s on a price-earnings basis, framing the latest advance in the context of a wider recovery in the shares.Investing.com
Conference focus and analyst attention today
Today, attention around Genmab centers on its participation in the Morgan Stanley 24th Annual Global Healthcare Conference, where management discussed the antibody pipeline and upcoming data catalysts, as reflected in a transcript dated September 15, 2026.MarketScreener In parallel, HC Wainwright reaffirmed its Buy rating on Genmab with a target price of USD 40.00 in a note published on September 15, 2026, highlighting expectations for future earnings and pipeline progress.MarketBeat As IT-Boltwise reported, the reiterated USD 40.00 target stands above a recent Nasdaq reference level around USD 32.47 from September 14, 2026, implying more than 20% upside potential and adding a supportive backdrop ahead of today’s session.IT-Boltwise
